drugset / Trial / NCT00371488
GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is two-part study (Phase I/Phase II). Part I is designed to find the optimal (best) doses of GW572016 and trastuzumab when given together,Part II is designed to evaluate the tumor response rate (shrinkage or lack of growth) in patients receiving lapatinib and trastuzumab.
Timeline
- Start
- 2006-04-06
- Primary completion
- 2007-12-10
- Completion
- 2007-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 750 mg | Oral |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |